Pds biotech to participate in cantor's future of oncology virtual symposium

Florham park, n.j., march 29, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that dr. frank bedu-addo, president and chief executive officer, will participate in cantor's future of oncology virtual symposium being held on april 3-5, 2023.
PDSB Ratings Summary
PDSB Quant Ranking